Navigation Links
Joslin Diabetes Center Convenes Leaders in Diabetes Prevention, Treatment, Payment, Education and Research at Diabetes Innovation 2012
Date:7/18/2012

BOSTON, July 18, 2012 /PRNewswire/ -- The diabetes epidemic demands a powerful response from leaders in the diabetes community, nationally and globally.  To this end, for the first time in its 114 year history, Joslin Diabetes Center, an affiliate of Harvard Medical School will convene all stakeholders for  a groundbreaking, immersive activity over 3 days in September called  Diabetes Innovation 2012 (September 23-25, 2012 at the Hyatt Crystal City in Arlington, VA). 

Diabetes Innovation 2012 will act as a powerful catalyst for ideas, partnerships and collaborations. It will provoke thought, innovation and action that address the cost, productivity and quality-of-life impact of diabetes on our society by bringing together all stakeholders:  payers, purchasers, providers, industry, government, research, patients, consumers, technologists, developers, and funders. 

"Simply put, we MUST forge new approaches and dramatically increase our sense of urgency to address diabetes head-on.  Despite all of our collective efforts, we are not keeping up with the global threats presented by obesity and diabetes," says John L. Brooks III, CEO, Joslin Diabetes Center. "To effectively make a real difference, we need to convene, apply our collective energies, and work together, to truly create innovative policies and programs that will involve all stakeholders and that will make a real difference.  This world-wide pandemic will not be solved until all of us use our combined resources, commitment, determination, and passion to map out an aggressive and meaningful path forward."

Diabetes Innovation 2012 will provide a powerful foundation for sustained advancement in all facets of diabetes prevention, treatment and payment reforms including social media and gaming, translational research breakthroughs, food sourcing, distribution to mobile patient technologies and everything in between. 

"Diabetes is the seventh leading cause of death in the U.S.  We need more preventive programs that help improve individuals' health and sustain behavior change.  When consumers make better choices about diet, exercise and smoking, potentially disastrous outcomes like diabetes and heart disease can be avoided," said Donald M. Berwick, MD, former CMS Administrator and former President and CEO, Institute for Healthcare Improvement and Diabetes Innovation 2012 Senior Advisor. "We need to 'innovate' processes, tools and incentives towards prevention for consumers and all stakeholders."

Diabetes Innovation 2012 features leaders and innovators from all sectors, and will include innovations in prevention, delivery and adherence as well as innovations in process and policy.  Among over 80 faculty, and hundreds of audience members, from industry and the payer, provider and purchaser community and academia, leaders from many of the most important government agencies (AHRQ, PCORI, NIH, CDC, FDA, CMS, CMMI) will be on hand to encourage open dialogue and collaboration to speed system improvements.

Support for the activity is provided by Sanofi US.  According to Dennis Urbaniak, Vice President, Head of U.S. Diabetes, Sanofi US, "At Sanofi, we know innovation is the key to fostering accelerated improvements. We are pleased to provide opportunities that stimulate innovation not only in products, but also in other solutions, as evidenced by our Data Design Diabetes Innovation Challenge. We're committed to supporting Joslin Diabetes Center's important initiative to convene all stakeholders onto common ground, to move forward as collaborators, and not as individual constituencies."

"Our very successful pilot of this convening event that we held in Washington DC last July, convinced us that there is a tremendous amount of interest and enthusiasm for expanding  this program to a three day program so we can engage as many participants and encompass as many ideas and inputs as possible," according to Brooks. "If you really want to shape the future direction of diabetes, covering the entire spectrum of care, education, technology, prevention as well as the landscape of diabetes complications, comorbidities, and related health conditions, you should sign up now so your voice can be heard."

To sponsor, exhibit or register for Diabetes Innovation 2012, please visit www.diabetesinnovation.org.

About Joslin Diabetes Center

Joslin Diabetes Center is the world leader in diabetes research, clinical care and education.   Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real hope and progress toward diabetes prevention and a cure.  Joslin is an independent, nonprofit institution affiliated with Harvard Medical School.  Our mission is to prevent, treat and cure diabetes.  Our vision is a world free of diabetes and its complications.  For more information, visit www.joslin.org.


'/>"/>
SOURCE Joslin Diabetes Center
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Whats Next In Vaccines (Malaria, Diabetes, Alzheimers, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline)
2. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
3. Lilly Diabetes Announces Once Upon A Time Contest Winner
4. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
5. Diabetes Care Devices in Emerging Countries (China, India, Brazil) to 2017 - Greater Awareness is Increasing Demand for Self-Monitoring of Blood Glucose (SMBG) in the Home Care Segment
6. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
7. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
8. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
9. Governor Gregoire and Congressman McDermott Join Novo Nordisk at Opening Event for Type 1 Diabetes Research Center in Seattle
10. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
11. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 2017 A new Transparency Market Research report ... valued at US$0.53 bn in 2013 and is predicted to touch ... between 2014 and 2022. The title of the report is "Non-invasive ... Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), also referred to ...
(Date:1/23/2017)... SAN DIEGO , 23 janvier 2017  ResMed ... Winter Haven , Floride) ont annoncé aujourd,hui qu,ils se ... les litiges existants entre les parties. BMC et 3B ... de paiements de droits à ResMed, et ResMed effectuera ... à 3B pour clore le litige de Floride entre ...
(Date:1/23/2017)... Jan 23, 2017 NeuroVive Pharmaceutical AB ... signed a preclinical collaboration agreement with the Children,s Hospital of ... Falk , M.D., a US key opinion leader in the ... ... evaluate compounds from NeuroVive,s research program, NVP015, in certain experimental ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... 23, 2017 , ... “Life Under Blankets”: an entrancing story about one ... Under Blankets” is the creation of published author, Kimberly Mitchell, who earned her bachelor’s ... went on to pursue a master’s degree in education in the field of curriculum ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Valentine’s Day is a time when many people ... ones. For those who may be looking for the ideal present, Atlanta-based Perimeter Plastic ... get an additional $25 free. Or, spend $200 and get $50 free. , “A ...
(Date:1/22/2017)... FL (PRWEB) , ... January 22, 2017 , ... Zifam ... customers across the world, recently met with big-name retail buyers at the January ECRM ... evidence of efficacy and uses the utmost safety standards in all of its creations ...
(Date:1/22/2017)... TX (PRWEB) , ... January 22, 2017 , ... ... provide slow results. Often the results of a simple test will take days to ... Any Lab Test Now offers customers direct access to their lab tests, bypassing the ...
(Date:1/21/2017)... Raton, FL (PRWEB) , ... January 21, 2017 , ... ... Germany, announced it is bringing its product to the United States as part of ... over the last 25 years, Alcovit aims to reduce the productions of nasty toxins ...
Breaking Medicine News(10 mins):